FGFR2 and melanoma: Similarly, melanoma patients harboring FGFR2 Mut had a pronounced survival advantage over those with FGFR2 Wt (mOS: 60.00 months vs. 31.20 months; HR 0.60, 95%CI 0.37-0.88; P = 0.0366) (Figure 4B).